A cross-sectional study on the concordance between vaginal HPV DNA detection and type-specific antibodies in a multi-ethnic cohort of women from Amsterdam, the Netherlands – the HELIUS study

Table 4 Linear regression of antibody reactivities (MFI) and type-specific vaginal HPV detection; univariable and multivariable analyses

			Univariable			Multivariable^a
Vaginal HPV type detection	Geometric mean of antibody reactivities in MFI among DNA negative (95 % CI)	Geometric mean of antibody reactivities in MFI among DNA positive (95 % CI)	Back-transformed regression coefficient^b	95 % CI	P-value	Back-transformed regression coefficient^b	95 % CI	P-value
HPV-16	80 (70–90)	110 (72–167)	1.39	(0.83,2.31)	0.21	1.34	(0.82,2.17)	0.24
HPV-18	104 (95–112)	134 (83–216)	1.30	(0.84,2.00)	0.24	1.26	(0.81,1.93)	0.30
HPV-31	141 (126–157)	303 (203–455)	2.16	(1.34,3.48)	<0.001	1.68	(1.03,2.72)	0.04
HPV-33	80 (73–88)	128 (40–411)	1.59	(0.70,3.61)	0.26	1.17	(0.53,2.57)	0.69
HPV-45	78 (71–85)	120 (51–280)	1.54	(0.73,3.23)	0.26	1.34	(0.66,2.70)	0.42
HPV-52	90 (81–100)	147 (99–218)	1.63	(1.13,2.36)	0.01	1.30	(0.91,1.87)	0.15
HPV-58	85 (79–92)	165 (72–376)	1.93	(1.05,3.55)	0.03	1.52	(0.84,2.75)	0.16

CI, confidence interval; MFI, median fluorescence intensity. ^aMultivariable models adjusted for age in years, ethnicity, marital status, smoking in pack years, number of lifetime male sexual partners. For analytic purposes age was modeled using restricted cubic splines with knots at the 5th, 35th, 65th and 95th percentile. ^bThe back-transformed regression coefficient for antibody reactivities is interpreted as being the factor by which the geometric mean of antibody reactivities of vaginal HPV DNA positive women is higher in comparison to women who do not have vaginal HPV DNA. For example, women in whom vaginal HPV-31 DNA was detected have a median antibody reactivity which is 2.16 times higher than the antibody reactivity of HPV-31 DNA negative women

ISSN: 1471-2334